Hane Chow
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
236 2nd St, Oakland, California, 94607, ...Phone Number
(510) 302-0590Website
www.hanechow.comRevenue
<$5 MillionIndustry
About Hane Chow
Hane Chow Org Chart
Is Hane Chow your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Hane Chow had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Hane Chow has new funding data
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Hane Chow launches new products
Earning: See what the market has to say on Hane Chow recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Hane Chow
Check if Hane Chow has recently received funding, and reach out quickly before it becomes old news!
Hane Chow, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Hane Chow is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Hane Chow as Masked Content
Find 2 more new buyers
Compare Similar Companies to Hane Chow
Compare insights from companies similar to Hane Chow, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Hane Chow is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Hane Chow is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Hane Chow.
Hane Chow financials insights
Gather financial insights about Hane Chow, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Debt
$85K
Hane Chow Tech Stack
A closer look at the technologies used by Hane Chow
Hane Chow News & Media
Aduro Biotech Presents Preliminary Results from Ongoing Phase 1 Trials of STING agonist ADU-S100 (MIW815) in Patients with Advanced Solid Tumors or Lymphomas
Data presented at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting demonstrate ADU-S100 (MIW815) is well-tolerated with no dose-limiting toxicities reported Preliminary signs of clinical and biomarker activity observed in patients with advanced cancers, including those pretreated with checkpoint inhibitor therapy Single agent data supports further evaluation of ADU-S100 in combination with checkpoint inhibitor therapies ADU-S100 is currently in a combination trial with investigaAduro Biotech Presents Preliminary Results from Ongoing Phase 1 Trials of STING agonist ADU-S100 (MIW815) in Patients with Advanced Solid Tumors or Lymphomas
Data presented at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting demonstrate ADU-S100 (MIW815) is well-tolerated with no dose-limiting toxicities reported Preliminary signs of clinical and biomarker activity observed in patients with advanced cancers, including those pretreated with checkpoint inhibitor therapy Single agent data supports further evaluation of ADU-S100 in combination with checkpoint inhibitor therapies ADU-S100 is currently in a combination trial with investigaLeap Therapeutics Reports Third Quarter 2018 Business Update and Financial Results
CAMBRIDGE, Mass., Nov. 9, 2018 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported a business update and financial results for the third quarter ended September 30, 2018. "Our team has executed extremely well over the past quarter, rapidly enrolling multiple clinical trials and presenting impressive clinical and preclinical data for both of our programs. We are excited about the potential for our DKLeap Therapeutics Presents Esophagogastric Cancer Data at SITC 2018 Annual Meeting
CAMBRIDGE, Mass., Nov. 9, 2018 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today presented clinical data from its ongoing Phase I/II study of DKN-01 in combination with paclitaxel in patients with advanced esophagogastric cancer at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting (SITC 2018). The esophagogastric cancer clinical trial (P102) is a multipart study of DKN-01 as a monotherapy and in combination with paclitaxel or pembrolizumab. The arms evaluating DKN-01
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Hane Chow
Hane Chow Inc. specializes in graphic design and website development, focusing on creating solutions that help clients stand out and add strategic value to their corporate communications. The company is dedicated to managing projects personally and ensuring effective communication with clients to achieve the highest level of success. Their portfoli... Read More